vitamin K epoxide reductase complex subunit 1
Senast uppdaterad 18 aug 2020
Uppfyller patientens redaktionella riktlinjer
- Ladda nerLadda ner
- Dela
- Language
- Diskussion
- Ask Patient
- Ljudversion
- Lägg till i föredragna källor på Google
Den VKORC1 gene provides instructions for making a vitamin K epoxide reductase enzyme. The VKORC1 enzyme is made primarily in the liver. It spans the membrane of a cellular structure called the endoplasmic reticulum, which is involved with protein processing and transport. The VKORC1 enzyme helps turn on (activate) clotting proteins in the pathway that forms blood clots. Specifically, the VKORC1 enzyme converts one form of vitamin K into a different form of vitamin K that assists in activating clotting proteins.
Videoval för GenesVideobibliotek
Normal function
Den VKORC1 gene provides instructions for making a vitamin K epoxide reductase enzyme. The VKORC1 enzyme is made primarily in the liver. It spans the membrane of a cellular structure called the endoplasmic reticulum, which is involved with protein processing and transport. The VKORC1 enzyme helps turn on (activate) clotting proteins in the pathway that forms blood clots. Specifically, the VKORC1 enzyme converts one form of vitamin K into a different form of vitamin K that assists in activating clotting proteins.
Conditions referring to this gene or chromosome
Other names
FLJ00289
vitamin K 1 2,3-epoxide reductase subunit 1
vitamin K epoxide reductase complex, subunit 1
VKOR
Related patient information and medicines

Patient information leaflet
Kan jag ta Warfarin och Vitamin K tillsammans?
Vitamin K can make warfarin less effective, which increases your risk of developing dangerous blood clots or having a stroke. Why this happens Warfarin works by blocking the way your body uses Vitamin K to make blood-clotting factors. Foods high in vitamin K (e.g. spinach, kale, broccoli, Brussels sprouts, asparagus) Vitamin K helps your blood to.

Patient information leaflet
Kan jag ta ingefära och vitamin C tillsammans?
Why this happens Ginger and vitamin C work through different pathways in the body and do not interfere with how the other is absorbed, broken down, or used. Ginger is primarily used for its anti-inflammatory and anti-nausea properties, while vitamin C is an antioxidant used for tissue repair and immune function. What you should do It is safe to.

Patient information leaflet
Kan jag ta Vitamin B12 och Vitamin C tillsammans?
Varför detta händer Vitamin C is an antioxidant that can chemically break down Vitamin B12 in the digestive tract, making the B12 inactive and harder for the body to absorb. Our Interaktionskontroll för läkemedel helps you check whether your prescriptions, over-the-counter medicines, and supplements are safe to take together. Disclaimer This information.

Patient information leaflet
Kan jag ta Solifenacin och Vitamin C tillsammans?
There is no known interaction between solifenacin and vitamin C (ascorbic acid). It is generally safe to take these two together. Why this happens Solifenacin is processed by the liver (specifically the CYP3A4 enzyme), while vitamin C is a water-soluble vitamin processed and excreted primarily by the kidneys. They do not share the same metabolic.

Patient information leaflet
Kan jag ta folsyra och vitamin C tillsammans?
In fact, taking them together is generally considered beneficial. Vitamin C can help prevent the breakdown of folic acid in the stomach, potentially making it easier for your body to use. Why this happens Vitamin C (ascorbic acid) acts as an antioxidant that helps stabilise folate (folic acid) in the digestive tract, protecting it from oxidative.

Patient information leaflet
Kan jag ta Ashwagandha och Vitamin C tillsammans?
Health benefits, uses, and... They do not share the same metabolic pathways in the liver, nor do they interfere with each other's absorption or excretion. Ashwagandha is an adaptogenic herb that works primarily on the body's stress response system (the adrenal glands), while vitamin C is a water-soluble antioxidant. How to take ashwagandha and.
Vidare läsning och referenser
- vitamin K epoxide reductase complex subunit 1; MedlinePlus, National Library of Medicine.
- Ferder NS, Eby CS, Deych E, Harris JK, Ridker PM, Milligan PE, Goldhaber SZ, King CR, Giri T, McLeod HL, Glynn RJ, Gage BF. Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost. 2010 Jan;8(1):95-100. doi: 10.1111/j.1538-7836.2009.03677.x. Epub 2009 Oct 30.
- Flockhart DA, O'Kane D, Williams MS, Watson MS, Flockhart DA, Gage B, Gandolfi R, King R, Lyon E, Nussbaum R, O'Kane D, Schulman K, Veenstra D, Williams MS, Watson MS; ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med. 2008 Feb;10(2):139-50. doi: 10.1097/GIM.0b013e318163c35f.
- Kaye JB, Schultz LE, Steiner HE, Kittles RA, Cavallari LH, Karnes JH. Warfarin Pharmacogenomics in Diverse Populations. Pharmacotherapy. 2017 Sep;37(9):1150-1163. doi: 10.1002/phar.1982. Epub 2017 Sep 6.
- Kurnik D, Qasim H, Sominsky S, Lubetsky A, Markovits N, Li C, Stein CM, Halkin H, Gak E, Loebstein R. Effect of the VKORC1 D36Y variant on warfarin dose requirement and pharmacogenetic dose prediction. Thromb Haemost. 2012 Oct;108(4):781-8. doi: 10.1160/TH12-03-0151. Epub 2012 Aug 7.
- Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. Identification of the gene for vitamin K epoxide reductase. Nature. 2004 Feb 5;427(6974):541-4. doi: 10.1038/nature02254.
- Lund K, Gaffney D, Spooner R, Etherington AM, Tansey P, Tait RC. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates. Br J Haematol. 2012 Jul;158(2):256-261. doi: 10.1111/j.1365-2141.2012.09150.x. Epub 2012 May 10.
- Watzka M, Geisen C, Bevans CG, Sittinger K, Spohn G, Rost S, Seifried E, Muller CR, Oldenburg J. Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment. J Thromb Haemost. 2011 Jan;9(1):109-18. doi: 10.1111/j.1538-7836.2010.04095.x.
Artikelhistorik
Artikeln finns också på Engelska, Tyska, Spanska, Franska, Italienska, Portugisiska, Hindi, Hebreiska, Arabiska, och Svenska.
18 aug 2020 | Senaste versionen
1 Jul 2015 | Ursprungligen publicerad
Dela dina tankar eller erfarenheter med andra i vår patientgemenskaper.
Anmäl dig till Patientens nyhetsbrev
Din veckovisa dos av tydliga, pålitliga hälsoråd - skrivna för att hjälpa dig känna dig informerad, självsäker och i kontroll.
Genom att prenumerera accepterar du våra Sekretesspolicy. Du kan avsluta prenumerationen när som helst. Vi säljer aldrig dina uppgifter.

